EZH2 and epithelioid sarcoma: Currently, there is only one EZH2 inhibitor tazemetostat approved by FDA for advanced epithelioid sarcoma and follicular lymphoma328,329 while other EZH2 inhibitors are still being tested in phase I/II clinical trials.